Literature DB >> 15834937

MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.

Carlo Alessandria1, Osman Ozdogan, Mónica Guevara, Tea Restuccia, Wladimiro Jiménez, Vicente Arroyo, Juan Rodés, Pere Ginès.   

Abstract

Important progress has been made recently regarding the pathogenesis and treatment of hepatorenal syndrome (HRS). However, scant information exists about factors predicting outcome in patients with cirrhosis and HRS. Moreover, the prognostic value of the model of end-stage liver disease (MELD) score has not been validated in the setting of HRS. The current study was designed to assess the prognostic factors and outcome of patients with cirrhosis and HRS. The study included 105 consecutive patients with HRS. Forty-one patients had type 1 HRS, while 64 patients had type 2 HRS. Patients with type 1 HRS not only had more severe liver and renal failure than type 2 patients, they also had greater impairment of circulatory function, as indicated by lower arterial pressure and higher activation of vasoconstrictor factors. In the whole series, the median survival was 3.3 months. In a multivariate analysis of survival, only HRS type and MELD score were associated with an independent prognostic value. All patients with type 1 HRS had a high MELD score (> or =20) and showed an extremely poor outcome (median survival: 1 mo). By contrast, the survival of patients with type 2 HRS was longer and dependent on MELD score (> or =20, median survival 3 mo; <20, median survival 11 mo; P < .002). In conclusion, the outcome of patients with cirrhosis and HRS can be estimated by using two easily available variables, HRS type and MELD score. These data can be useful in the management of patients with HRS, particularly for patients who are candidates for liver transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 15834937     DOI: 10.1002/hep.20687

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  76 in total

1.  Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Authors:  Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Veit Gülberg; Samuel Sigal; Alice S Bexon; Peter Teuber
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

Review 2.  Renal impairment in cirrhosis unrelated to hepatorenal syndrome.

Authors:  Gavin Low; Graeme Jm Alexander; David J Lomas
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

Review 3.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 4.  [Hepatorenal syndrome].

Authors:  I Kürer; A Sommerer; G Puhl; U Kaisers; W Boemke
Journal:  Anaesthesist       Date:  2006-01       Impact factor: 1.041

Review 5.  [Hepatorenal syndrome].

Authors:  G Huschak; U X Kaisers; S Laudi
Journal:  Anaesthesist       Date:  2013-07       Impact factor: 1.041

6.  Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites.

Authors:  Gavin Low; Nicola E Owen; Ilse Joubert; Andrew J Patterson; Martin J Graves; Graeme J M Alexander; David J Lomas
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 7.  What's new in the treatment of ascites and spontaneous bacterial peritonitis.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  Curr Gastroenterol Rep       Date:  2008-02

8.  Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification.

Authors:  Eiichiro Okazaki; Akira Yamamoto; Norifumi Nishida; Masao Hamuro; Ryo Ogino; Masako Hosono; Yasuhiko Shimatani; Shinichi Tsutsumi; Shinichi Hamamoto; Etsuji Sohgawa; Atsushi Jogo; Yukio Miki
Journal:  Br J Radiol       Date:  2016-05-10       Impact factor: 3.039

9.  Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study.

Authors:  Anna Licata; Marcello Maida; Ambra Bonaccorso; Fabio Salvatore Macaluso; Maria Cappello; Antonio Craxì; Piero Luigi Almasio
Journal:  World J Hepatol       Date:  2013-12-27

10.  Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.

Authors:  Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez
Journal:  World J Hepatol       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.